Stephens analyst Scott Fidel lowered the firm’s price target on Tenet Healthcare (THC) to $260 from $275 and keeps an Overweight rating on the shares. The firm adjusted estimates following Tenet’s Q1 report.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Buy Rating Reiterated on Tenet Healthcare as Strong Q1 Execution Supports Upside; $242 Price Target Maintained
- Tenet Healthcare price target lowered to $254 from $260 at Morgan Stanley
- Tenet Healthcare selloff overdone, compelling longer term, says Cantor
- Tenet Healthcare price target lowered to $225 from $250 at KeyBanc
- Tenet Healthcare price target lowered to $252 from $283 at Guggenheim